IGF signaling defects as causes of growth failure and IUGR

Trends in Endocrinology and Metabolism

Volumn 19, Issue 6, 2008, Pages 197-205

  Klammt, Jürgen ^a   Pfäffle, Roland ^a   Werner, Haim ^b   Kiess, Wieland ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; SOMATOMEDIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; GESTATIONAL AGE; GROWTH DISORDER; INTRAUTERINE GROWTH RETARDATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMALL FOR DATE INFANT;

ANIMALS; FEMALE; FETAL GROWTH RETARDATION; HUMANS; INFANT, NEWBORN; INFANT, SMALL FOR GESTATIONAL AGE; MODELS, BIOLOGICAL; PREGNANCY; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 47249134315     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2008.03.003     Document Type: Review

References (86)

1. Dupont J., and Holzenberger M. Biology of insulin-like growth factors in development. Birth Defects Res. C. Embryo Today 69 (2003) 257-271
2. Rodriguez S., et al. Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease. Hum. Genet. 122 (2007) 1-21
3. Saenger P., et al. Small for gestational age: short stature and beyond. Endocr. Rev. 28 (2007) 219-251
4. Walenkamp M.J., and Wit J.M. Genetic disorders in the growth hormone - insulin-like growth factor-I axis. Horm. Res. 66 (2006) 221-230
5. Laviola L., et al. The IGF-I signaling pathway. Curr. Pharm. Des. 13 (2007) 663-669
6. Rosenfeld R.G., et al. Defects in growth hormone receptor signaling. Trends Endocrinol. Metab. 18 (2007) 134-141
7. Abuzzahab M.J., et al. IGF-I receptor mutations resulting in intrauterine and postnatal growth retardation. N. Engl. J. Med. 349 (2003) 2211-2222
8. Raile K., et al. Clinical and functional characteristics of the human Arg59Ter insulin-like growth factor i receptor (IGF1R) mutation: implications for a gene dosage effect of the human IGF1R. J. Clin. Endocrinol. Metab. 91 (2006) 2264-2271
9. Musso C., et al. Clinical course of genetic diseases of the insulin receptor (type A and Rabson-Mendenhall syndromes): a 30-year prospective. Medicine (Baltimore) 83 (2004) 209-222
10. Holzenberger M., et al. A targeted partial invalidation of the insulin-like growth factor I receptor gene in mice causes a postnatal growth deficit. Endocrinology 141 (2000) 2557-2566
11. Holzenberger M., et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 421 (2003) 182-187
12. Kulkarni R.N., et al. β-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter β-cell mass. Nat. Genet. 31 (2002) 111-115
13. Fernandez A.M., et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 15 (2001) 1926-1934
14. Araki E., et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372 (1994) 186-190
15. Tamemoto H., et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372 (1994) 182-186
16. Ogata N., et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J. Clin. Invest. 105 (2000) 935-943
17. Hoshi K., et al. Deficiency of insulin receptor substrate-1 impairs skeletal growth through early closure of epiphyseal cartilage. J. Bone Miner. Res. 19 (2004) 214-223
18. Gual P., et al. Positive and negative regulation of insulin signaling through IRS-1 phosphorylation. Biochimie 87 (2005) 99-109
19. Kubota N., et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes 49 (2000) 1880-1889
20. Taniguchi C.M., et al. Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. J. Clin. Invest. 115 (2005) 718-727
21. Withers D.J., et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391 (1998) 900-904
22. Withers D.J., et al. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat. Genet. 23 (1999) 32-40
23. Ford-Hutchinson A.F., et al. Inactivation of Pten in osteo-chondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth. J. Bone Miner. Res. 22 (2007) 1245-1259
24. Lawlor M.A., et al. Essential role of PDK1 in regulating cell size and development in mice. EMBO J. 21 (2002) 3728-3738
25. Hashimoto N., et al. Ablation of PDK1 in pancreatic beta cells induces diabetes as a result of loss of beta cell mass. Nat. Genet. 38 (2006) 589-593
26. Mora A., et al. Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia. EMBO J. 22 (2003) 4666-4676
27. Mora A., et al. Deficiency of PDK1 in liver results in glucose intolerance, impairment of insulin-regulated gene expression and liver failure. Biochem. J. 385 (2005) 639-648
28. Hinton H.J., et al. The serine kinase phosphoinositide-dependent kinase 1 (PDK1) regulates T cell development. Nat. Immunol. 5 (2004) 539-545
29. Sandu C., et al. Impaired intestinal NHE3 activity in the PDK1 hypomorphic mouse. Am. J. Physiol. Gastrointest. Liver Physiol. 291 (2006) G868-G876
30. Easton R.M., et al. Role for Akt3/protein kinase B gamma in attainment of normal brain size. Mol. Cell. Biol. 25 (2005) 1869-1878
31. Tschopp O., et al. Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 132 (2005) 2943-2954
32. Cho H., et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292 (2001) 1728-1731
33. Garofalo R.S., et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J. Clin. Invest. 112 (2003) 197-208
34. Chen W.S., et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev. 15 (2001) 2203-2208
35. Cho H., et al. Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J. Biol. Chem. 276 (2001) 38349-38352
36. Yang Z.Z., et al. Protein kinase B alpha/Akt1 regulates placental development and fetal growth. J. Biol. Chem. 278 (2003) 32124-32131
37. Carpten J.D., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448 (2007) 439-444
38. Murphy V.E., et al. Endocrine regulation of human fetal growth: the role of the mother, placenta, and fetus. Endocr. Rev. 27 (2006) 141-169
39. Shima H., et al. Disruption of the p70(s6k)/p85(s6k) gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17 (1998) 6649-6659
40. Pende M., et al. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol. Cell. Biol. 24 (2004) 3112-3124
41. Ruvinsky I., et al. Ribosomal protein S6 phosphorylation is a determinant of cell size and glucose homeostasis. Genes Dev. 19 (2005) 2199-2211
42. Pende M., et al. Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice. Nature 408 (2000) 994-997
43. Um S.H., et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431 (2004) 200-205
44. Manning B.D. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J. Cell Biol. 167 (2004) 399-403
45. Backeljauw P.F., and Chernausek S.D. Treatment of insulin-like growth factor deficiency with IGF-I: studies in humans. Horm. Res. 65 Suppl. 1 (2006) 21-27
46. Reiter E.O. Hormonal treatment of idiopathic short stature. Horm. Res. 67 Suppl. 1 (2007) 58-63
47. Gluckman P.D., and Hanson M.A. The consequences of being born small - an adaptive perspective. Horm. Res. 65 Suppl. 3 (2006) 5-14
48. Fernandez-Twinn D.S., and Ozanne S.E. Mechanisms by which poor early growth programs type-2 diabetes, obesity and the metabolic syndrome. Physiol. Behav. 88 (2006) 234-243
49. Ong K.K. Size at birth, postnatal growth and risk of obesity. Horm. Res. 65 Suppl. 3 (2006) 65-69
50. Vaessen N., et al. Association between genetic variation in the gene for insulin-like growth factor-I and low birthweight. Lancet 359 (2002) 1036-1037
51. Frayling T.M., et al. Conflicting results on variation in the IGFI gene highlight methodological considerations in the design of genetic association studies. Diabetologia 45 (2002) 1605-1606
52. Fowden A.L. The insulin-like growth factors and feto-placental growth. Placenta 24 (2003) 803-812
53. Ostlund E., et al. Transforming growth factor-beta1 in fetal serum correlates with insulin-like growth factor-I and fetal growth. Obstet. Gynecol. 100 (2002) 567-573
54. Laviola L., et al. Intrauterine growth restriction in humans is associated with abnormalities in placental insulin-like growth factor signaling. Endocrinology 146 (2005) 1498-1505
55. Roos S., et al. Mammalian target of rapamycin in the human placenta regulates leucine transport and is down-regulated in restricted fetal growth. J. Physiol. 582 (2007) 449-459
56. Gluckman P.D., and Hanson M.A. The developmental origins of the metabolic syndrome. Trends Endocrinol. Metab. 15 (2004) 183-187
57. Bachman K.E., et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 3 (2004) 772-775
58. Campbell I.G., et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64 (2004) 7678-7681
59. Werner H., and Maor S. The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor suppressor action. Trends Endocrinol. Metab. 17 (2006) 236-242
60. Morgensztern D., and McLeod H.L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16 (2005) 797-803
61. Granville C.A., et al. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin. Cancer Res. 12 (2006) 679-689
62. Woods K.A., et al. Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. N. Engl. J. Med. 335 (1996) 1363-1367
63. Bonapace G., et al. A novel mutation in a patient with insulin-like growth factor 1 (IGF1) deficiency. J. Med. Genet. 40 (2003) 913-917
64. Walenkamp M.J., et al. Homozygous and heterozygous expression of a novel insulin-like growth factor-I mutation. J. Clin. Endocrinol. Metab. 90 (2005) 2855-2864
65. Kawashima Y., et al. Mutation at cleavage site of insulin-like growth factor receptor in a short-stature child born with intrauterine growth retardation. J. Clin. Endocrinol. Metab. 90 (2005) 4679-4687
66. Inagaki K., et al. A familial insulin-like growth factor-I receptor mutant leads to short stature: clinical and biochemical characterization. J. Clin. Endocrinol. Metab. 92 (2007) 1542-1548
67. Walenkamp M.J., et al. A variable degree of intrauterine and postnatal growth retardation in a family with a missense mutation in the insulin-like growth factor I receptor. J. Clin. Endocrinol. Metab. 91 (2006) 3062-3070
68. Kawashima, Y. et al. (2006) A family with short stature born intrauterine growth retardation bearing a new missense mutation at subunit of IGF-I receptor (R431L) (abstract). The Endocrine Society's 88th Annual Meeting 2006, P2-117:426
69. Burks D.J., et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 407 (2000) 377-382
70. Lai K.M., and Pawson T. The ShcA phosphotyrosine docking protein sensitizes cardiovascular signaling in the mouse embryo. Genes Dev. 14 (2000) 1132-1145
71. Cheng A.M., et al. Mammalian Grb2 regulates multiple steps in embryonic development and malignant transformation. Cell 95 (1998) 793-803
72. Qian X., et al. The Sos1 and Sos2 Ras-specific exchange factors: differences in placental expression and signaling properties. EMBO J. 19 (2000) 642-654
73. Esteban L.M., et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol. Cell. Biol. 21 (2001) 1444-1452
74. Johnson L., et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11 (1997) 2468-2481
75. Mikula M., et al. Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene. EMBO J. 20 (2001) 1952-1962
76. Giroux S., et al. Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr. Biol. 9 (1999) 369-372
77. Belanger L.F., et al. Mek2 is dispensable for mouse growth and development. Mol. Cell. Biol. 23 (2003) 4778-4787
78. Pages G., et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 286 (1999) 1374-1377
79. Saba-El-Leil M.K., et al. An essential function of the mitogen-activated protein kinase Erk2 in mouse trophoblast development. EMBO Rep. 4 (2003) 964-968
80. Bi L., et al. Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. J. Biol. Chem. 274 (1999) 10963-10968
81. Bi L., et al. Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mamm. Genome 13 (2002) 169-172
82. Okkenhaug K., et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297 (2002) 1031-1034
83. Terauchi Y., et al. Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase. Nat. Genet. 21 (1999) 230-235
84. Fruman D.A., et al. Hypoglycaemia, liver necrosis and perinatal death in mice lacking all isoforms of phosphoinositide 3-kinase p85 alpha. Nat. Genet. 26 (2000) 379-382
85. Chen D., et al. p50alpha/p55alpha phosphoinositide 3-kinase knockout mice exhibit enhanced insulin sensitivity. Mol. Cell. Biol. 24 (2004) 320-329
86. Ueki K., et al. Increased insulin sensitivity in mice lacking p85beta subunit of phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 419-424